Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday.
According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
Get Amphastar Pharmaceuticals alerts:
A number of other equities analysts have also commented on AMPH. BidaskClub raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, January 19th. Piper Jaffray reaffirmed a “buy” rating and set a $26.00 price target on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 price target (up from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BMO Capital Markets reaffirmed a “market perform” rating and set a $19.00 price target (up from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. Finally, Wells Fargo reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.33.
Amphastar Pharmaceuticals opened at $16.00 on Tuesday, Marketbeat.com reports. Amphastar Pharmaceuticals has a 52 week low of $15.75 and a 52 week high of $15.99. The stock has a market cap of $725.78 million, a P/E ratio of 42.11, a price-to-earnings-growth ratio of 2.33 and a beta of 1.42. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.53 and a current ratio of 2.40.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, May 9th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.13). Amphastar Pharmaceuticals had a positive return on equity of 3.39% and a negative net margin of 1.50%. The business had revenue of $58.40 million for the quarter, compared to the consensus estimate of $60.75 million. During the same period in the prior year, the business posted $0.09 earnings per share. Amphastar Pharmaceuticals’s revenue was up 3.0% compared to the same quarter last year. equities research analysts anticipate that Amphastar Pharmaceuticals will post 0.3 earnings per share for the current year.
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 19,801 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total value of $398,000.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Jason B. Shandell sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $19.43, for a total transaction of $388,600.00. Following the completion of the transaction, the insider now directly owns 251,372 shares in the company, valued at $4,884,157.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,099 shares of company stock worth $1,131,215. Insiders own 31.50% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 1,746.9% in the 4th quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock valued at $5,650,000 after purchasing an additional 277,771 shares in the last quarter. Cortina Asset Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at approximately $4,907,000. Mackay Shields LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at approximately $4,294,000. Dimensional Fund Advisors LP boosted its stake in shares of Amphastar Pharmaceuticals by 17.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after purchasing an additional 226,271 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Amphastar Pharmaceuticals by 156.1% in the 4th quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock valued at $3,392,000 after purchasing an additional 107,486 shares in the last quarter. 44.94% of the stock is currently owned by hedge funds and other institutional investors.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com